Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Onvapegleukin alfa - Ascendis Pharma

Next Previous
Drug Profile

Onvapegleukin alfa - Ascendis Pharma

Alternative Names: TransCon IL-2 b/g; TransCon IL-2 β/γ; TransCon Interleukin 2 beta/gamma - Ascendis Pharma

Latest Information Update: 21 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ascendis Pharma
  • Class Adjuvants; Antineoplastics; Interleukins; Lymphokines
  • Mechanism of Action Interleukin receptor common gamma subunit stimulants; Interleukin-2 receptor beta subunit agonists; Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Squamous cell cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 28 Mar 2025 Ascendis Pharma completes phase-II clinical trials in Squamous cell cancer (Combination therapy, First-line therapy, Late-stage disease) in Taiwan, Spain, Poland, Italy, Hungary, Germany, Georgia (Intratumoural) (NCT05980598)
  • 13 Sep 2024 Efficacy, pharmacodyanmics and adverse events data from the phase I/II trial in Solid tumours presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)
  • 13 Sep 2024 Efficacy data from a phase I/II IL Believe trial in Solid tumours released by Ascendis Pharma

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top